AIDX 20/20 Biolabs, Inc.
NasdaqResearch view
20/20 Biolabs, Inc. operates in the Services-Testing Laboratories industry.
$0.261−5.27%
Oct 16 close · 1D EOD · Databento
IndustrialsServices-Testing LaboratoriesMicro-capSEC EDGAR FY 2025-12-31
On the WireNo stories on AIDX yet. Follow the company and the next one lands in Following.
The numbers · FY2025, filed
SEC EDGARMarket cap$3M
Revenue$2.0M+16.70%
Net income$-3.7M
EPS, diluted$-0.76+34.50%
Gross margin29.6%
Operating margin-162.9%
All filed figures
Snapshot
SEC EDGAR · FY 2025-12-31SectorIndustrials
Market Cap$2.8M
Enterprise Value$1.7M
Income$-3.7M
Sales$2.0M
Book/sh$0.00
Cash/sh$0.08
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio0.55
Current Ratio0.60
Debt/Eq—
EPS (ttm)$-0.76
EPS this Y34.5%
EPS past 3/5Y—
Sales past 3/5Y—
EPS Y/Y TTM34.5%
Sales Y/Y TTM16.7%
Shs Outstand12.77M
ROA-90.4%
ROE19447.7%
ROIC—
Gross Margin29.6%
Oper. Margin-162.9%
Profit Margin-182.8%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue by fiscal year
$1.8M
FY24
$2.0M
FY25
Operating leverage — margins
GrossOperatingNet
Financials, annual · income and cash flowSEC EDGAR · open ▸
Financials — annual
SEC EDGAR · last 2 FY · tap a row to explain it| USD | FY2024 | FY2025 |
|---|---|---|
| Revenue | $1.8M | $2.0M |
| Gross Profit | $360,311 | $604,541 |
| Operating Income | $-5.7M | $-3.3M |
| Net Income | $-5.6M | $-3.7M |
| Diluted EPS | $-1.16 | $-0.76 |
| Operating Cash Flow | $-2.6M | $-1.9M |
| Free Cash Flow | — | — |
Same industry
In the screener →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.